Resolution, improvement, and duration of PN (SMQ) in the safety population
| . | Brentuximab vedotin (n = 44) . | Physician’s choice (n = 4) . | ||
|---|---|---|---|---|
| Data cutoff . | 31 May 2016 . | 28 September 2018 . | 31 May 2016 . | 28 September 2018 . |
| Patients with resolution or improvement of PN events, n (%) Patients with resolution of all PN events, n (%) Median time to resolution, wk Patients with improvement in PN events by ≥1 grade, n (%) Median time to improvement, wk | 36 (82) 22 (50) 27.0 14 (32) 8.0 | 38 (86) 26 (59) 33.0 12 (27) 15.0 | 1 (25) 1 (25) 2.0 0 — | 2 (50) 2 (50) 10.5 0 — |
| Patients with ongoing PN events, n (%) Maximum severity grade 1, n (%) Maximum severity grade 2, n (%) | 22 (50) 17 (39) 5 (11) | 18 (41) 15 (34) 3 (7) | 3 (75) 1 (25) 2 (50) | 2 (50) 1 (25) 1 (25) |
| . | Brentuximab vedotin (n = 44) . | Physician’s choice (n = 4) . | ||
|---|---|---|---|---|
| Data cutoff . | 31 May 2016 . | 28 September 2018 . | 31 May 2016 . | 28 September 2018 . |
| Patients with resolution or improvement of PN events, n (%) Patients with resolution of all PN events, n (%) Median time to resolution, wk Patients with improvement in PN events by ≥1 grade, n (%) Median time to improvement, wk | 36 (82) 22 (50) 27.0 14 (32) 8.0 | 38 (86) 26 (59) 33.0 12 (27) 15.0 | 1 (25) 1 (25) 2.0 0 — | 2 (50) 2 (50) 10.5 0 — |
| Patients with ongoing PN events, n (%) Maximum severity grade 1, n (%) Maximum severity grade 2, n (%) | 22 (50) 17 (39) 5 (11) | 18 (41) 15 (34) 3 (7) | 3 (75) 1 (25) 2 (50) | 2 (50) 1 (25) 1 (25) |